A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults and Adults With FV Leiden or Prothrombin G20210A Mutation
Clinical trial NCT07430397 · RECRUITING
Trial details
- NCT number
- NCT07430397
- Sponsor
- City Therapeutics
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-22
- Primary completion
- 2027-08-01
- Enrollment
- 128
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.